drugset / Trial / NCT01476696

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

NCT01476696

Phase 2 Completed 33 enrolled Eli Lilly and Company Daiichi Sankyo · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the correct prasugrel dosage to be given to children with sickle cell disease (SCD).

Timeline

Start
2011-11
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Prasugrel Small molecule 0.03 mg/kg Oral
Subject Prasugrel Small molecule 0.6 mg/kg Oral

Indications